<DOC>
	<DOCNO>NCT00582985</DOCNO>
	<brief_summary>This study perform evaluate safety tolerability TRC105 monoclonal antibody .</brief_summary>
	<brief_title>Open Label Phase 1 Dose Finding Study TRC105 Patients With Solid Cancer</brief_title>
	<detailed_description>In addition safety , study also evaluate pharmacokinetics , tumor response anti-TRC105 antibody formation .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The patient give informed consent . The patient willing able abide protocol . The patient cancer curative therapy unavailable . The patient least 18 year old . The patient adequate ability perform activity daily live . Significant toxicity prior therapy must recover . The patient adequate organ function assess laboratory test . The patient weigh 264 lb . The patient know allergy gentamicin The patient prior treatment highdose chemotherapy require stem cell rescue The patient currently treatment another therapeutic clinical trial receive investigational agent within 4 week prior first dose study drug The patient prior surgery ( include open biopsy ) , radiation therapy systemic therapy within 4 week start study treatment The patient hypertension &gt; 160/90 The patient history CNS cancer The patient unstable medical condition include , limited , cardiac disease , history stroke , active hepatitis , significant pericardial , pleural peritoneal effusion The patient receive recent thrombolytic anticoagulant therapy The patient lung cancer central chest lesions The patient hemorrhage unhealed wound within 30 day dose The patient use systemic corticosteroid within 3 month dose The patient know HIV/AIDS The patient history hypersensitivity reaction human mouse antibody product The patient pregnant breastfeeding . The patient history peptic ulcer disease gastritis within 6 month dose , unless complete resolution document esophagogastroduodenoscopy ( EGD ) within 30 day dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Tracon</keyword>
	<keyword>CD105</keyword>
	<keyword>Anti CD105</keyword>
	<keyword>TRC105</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Cancer</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>